Placeholder Banner

Brief of Amicus Curiae Biotechnology Innovation Organization in Support of Plaintiffs-Appellees in Amgen Inc. v. Apotex Inc. (U.S. Court of Appeals for the Federal Circuit)

February 16, 2016

Brief of Amicus Curiae Biotechnology Innovation Organization in Support of Plaintiffs-Appellees in Amgen Inc. v. Apotex Inc. (U.S. Court of Appeals for the Federal Circuit)

INTEREST OF AMICUS CURIAE
 
The Biotechnology Innovation Organization (“BIO”) is the world’s largest
biotechnology trade organization, representing more than 1,000 member
companies and research organizations—from startups to Fortune 500 companies—
who research and develop biotechnological products including lifesaving
medicines. Biological medicines are now used to treat previously untreatable
diseases and have prolonged and improved the lives of countless patients. But,
development of a biological medicine generally requires a decade or more of
research, as well as a fully capitalized investment that on average exceeds
$2 billion.
 
BIO played a leading role in the effort to establish a statutory pathway for
abbreviated approval of biosimilars that would lower costs through increased
competition and expand access to lifesaving medicines while protecting patient
safety and promoting further biomedical innovation. The aptly named Biologics
Price Competition and Innovation Act (“BPCIA” or “the Act”) aims to achieve those goals.
Many of BIO’s members are global leaders in the development and
commercialization of both innovative biologics and biosimilars. Accordingly, BIO
and its members have a strong interest in the proper interpretation of the critical
provision of the BPCIA at issue in this case.
 

 

Discover More
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…
BIO filed an amicus brief in the U.S. Court of Appeals for the Sixth Circuit, seeking the reversal of a lower court's ruling that would set aside the 2022 rescission of the Securities and Exchange Commission (SEC) 2020 Rule regulating proxy advisory…
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit on an important and recurring question concerning the framework for determining patent obviousness in patent litigation. BIO argues that courts, when considering whether…